Robert Castaigne - Sanofi ADR Independent Director

SNY Stock  USD 48.60  0.94  1.90%   

Director

Mr. Robert Castaigne no longer serves as Independent Director of Sanofi S.A., effective as of May 2, 2018. He has held this position since May 4, 2012. Prior to that, he served as Director of the Company from February 21, 2000 to May 4, 2012. He was Chairman of the Audit Committee of the Company. Additionally, Mr. Castaigne has served as Director of Vinci and Societe Generale. He has also acted as Member of the Audit, Internal Control and Risks Committee of Societe Generale, as well as Member of the Audit and Remuneration Committees of Vinci. Previously, he served as Director of Sanofi SA from February 21, 2000 to May 4, 2012. Until 2011, he held the posts of Director and Member of the Audit Committee of Compagnie Nationale a Portefeuille, among others. Between 1972 and 2008, he held various positions at the Total group, including Chief Financial Officer and Member of the Executive Committee . He was also Chairman and Chief Executive Officer of Total Chimie and of Total Nucleaire, amongst other positions
Age 70
Professional MarksPh.D
Address 46, avenue de la Grande Armée,, Paris, France, 75017
Phone33 1 53 77 40 00
Webhttps://www.sanofi.com
Castaigne holds a degree from Ecole Centrale Lille and Ecole Nationale Superieure du Petrole et des Moteurs, and also holds a Doctorate in Economics from Universite Paris I Pantheon Sorbonne.

Sanofi ADR Management Efficiency

The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.17 in 2024. Return On Assets is likely to rise to 0.08 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.
The company has 18.42 B in debt with debt to equity (D/E) ratio of 0.3, which may show that the company is not taking advantage of profits from borrowing. Sanofi ADR has a current ratio of 1.27, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Sanofi ADR until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi ADR's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi ADR's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Aida AlvarezWalmart
65
Martin SorrellAlcoa Corp
70
Larry FaulknerExxon Mobil Corp
70
Robert YostBank Of America
73
Rajiv GuptaAlcoa Corp
N/A
Robson WaltonWalmart
73
Roger CorbettWalmart
71
Carla HarrisWalmart
58
Susan AveryExxon Mobil Corp
70
Dambisa MoyoChevron Corp
52
Roger StoneMcDonalds
79
John RogersMcDonalds
62
James McNerneyInternational Business Machines
65
Marillyn HewsonChevron Corp
67
Mark FieldsInternational Business Machines
55
Kelly PasterickAlcoa Corp
N/A
Denise RamosBank Of America
64
Stanley ONealAlcoa Corp
63
Ursula BurnsExxon Mobil Corp
62
Alexis HermanThe Coca Cola
73
Thomas MayBank Of America
73
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 95442 people. Sanofi ADR (SNY) is traded on NASDAQ Exchange in USA. It is located in 46, avenue de la Grande Armée,, Paris, France, 75017 and employs 86,088 people. Sanofi ADR is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Sanofi ADR Leadership Team

Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Executive Counsel
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Executive VP of Legal Affairs and General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Madeleine Roach, Executive Operations
Pierre Chancel, Senior Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Sanofi Stock analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.217
Dividend Share
3.76
Earnings Share
2.33
Revenue Per Share
18.388
Quarterly Revenue Growth
0.029
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.